Details for Patent: 12,629,370
✉ Email this page to a colleague
Which drugs does patent 12,629,370 protect, and when does it expire?
Patent 12,629,370 protects ORGOVYX and is included in one NDA.
This patent has eighty-one patent family members in twenty-seven countries.
Drugs Protected by US Patent 12,629,370
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | ORGOVYX | relugolix | TABLET;ORAL | 214621-001 | Dec 18, 2020 | RX | Yes | Yes | 12,629,370 | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,629,370
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 109759 | ⤷ Start Trial | |||
| Argentina | 109762 | ⤷ Start Trial | |||
| Argentina | 110636 | ⤷ Start Trial | |||
| Australia | 2017334035 | ⤷ Start Trial | |||
| Australia | 2017336338 | ⤷ Start Trial | |||
| Australia | 2017336363 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
